221 related articles for article (PubMed ID: 8957159)
1. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia.
Wilde MI; McTavish D
Drugs; 1996 Dec; 52(6):883-98. PubMed ID: 8957159
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
[TBL] [Abstract][Full Text] [Related]
3. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.
Dunn CJ; Matheson A; Faulds DM
Drugs Aging; 2002; 19(2):135-61. PubMed ID: 11950378
[TBL] [Abstract][Full Text] [Related]
4. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.
Abrams P; Schulman CC; Vaage S
Br J Urol; 1995 Sep; 76(3):325-36. PubMed ID: 7551841
[TBL] [Abstract][Full Text] [Related]
5. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
Wilde MI; Fitton A; McTavish D
Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
[TBL] [Abstract][Full Text] [Related]
6. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
McKeage K; Plosker GL
Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
[TBL] [Abstract][Full Text] [Related]
7. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Chapple CR; Wyndaele JJ; Nordling J; Boeminghaus F; Ypma AF; Abrams P
Eur Urol; 1996; 29(2):155-67. PubMed ID: 8647141
[TBL] [Abstract][Full Text] [Related]
8. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
10. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
12. Tamsulosin for the treatment of benign prostatic hypertrophy.
Lee M
Ann Pharmacother; 2000 Feb; 34(2):188-99. PubMed ID: 10676828
[TBL] [Abstract][Full Text] [Related]
13. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
Eur Urol; 1996; 29(2):145-54. PubMed ID: 8647140
[TBL] [Abstract][Full Text] [Related]
14. Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
Lyseng-Williamson KA; Jarvis B; Wagstaff AJ
Drugs; 2002; 62(1):135-67. PubMed ID: 11790159
[TBL] [Abstract][Full Text] [Related]
15. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
Schulman CC
Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
[TBL] [Abstract][Full Text] [Related]
16. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
Chapple CR
Eur Urol; 1996; 29(2):129-44. PubMed ID: 8647139
[TBL] [Abstract][Full Text] [Related]
17. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.
Tsujii T
Int J Urol; 2000 Jun; 7(6):199-205. PubMed ID: 10843450
[TBL] [Abstract][Full Text] [Related]
18. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
Narayan P; Lepor H
Urology; 2001 Mar; 57(3):466-70. PubMed ID: 11248621
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
20. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Guay DR
Am J Geriatr Pharmacother; 2004 Mar; 2(1):14-23. PubMed ID: 15555475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
